Tag: biologics

29 Dec
Lot-to-Lot Variability in Biologics and Biosimilars: What It Means for Patients and Providers
Simon loxton

Lot-to-Lot Variability in Biologics and Biosimilars: What It Means for Patients and Providers

Lot-to-lot variability is a natural part of biologic and biosimilar manufacturing. Unlike generics, these drugs contain millions of slightly different protein versions in each batch. Learn how this variation is managed, why it doesn't affect safety, and what it means for patients and labs.

View More 12

recent posts

How to Monitor Kidney Function for Safe Senior Dosing
How to Monitor Kidney Function for Safe Senior Dosing

Published on: 19 Feb

REMS Programs Explained: How the FDA Manages High-Risk Medications
REMS Programs Explained: How the FDA Manages High-Risk Medications

Published on: 25 Feb

SGLT2 Inhibitors and Fournier’s Gangrene: Early Warning Signs and What to Do
SGLT2 Inhibitors and Fournier’s Gangrene: Early Warning Signs and What to Do

Published on: 11 Feb

Warfarin and NSAIDs: Understanding the Increased Bleeding Risk
Warfarin and NSAIDs: Understanding the Increased Bleeding Risk

Published on: 5 Feb

False Advertising in Generics: Legal Risks and Rules You Need to Know
False Advertising in Generics: Legal Risks and Rules You Need to Know

Published on: 7 Feb

categories

archives

tags